Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus OZOBAX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL AND ASPIRIN versus OZOBAX DS.
METHOCARBAMOL AND ASPIRIN vs OZOBAX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
None Documented
None Documented
Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline pH; biliary elimination <5%.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant